BIO-PATH HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIO-PATH HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 19, 2019 |
| FY2018 | Dec 31, 2017 | $37.0K | Mar 19, 2019 |
| FY2016 | Dec 31, 2016 | $13.0K | Mar 15, 2017 |
| FY2016 | Sep 30, 2016 | $0 | Mar 15, 2017 |
| FY2016 | Jun 30, 2016 | $0 | Mar 15, 2017 |
| FY2016 | Mar 31, 2016 | $0 | Mar 15, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Mar 15, 2017 |
| FY2016 | Sep 30, 2015 | $0 | Mar 15, 2017 |
| FY2016 | Jun 30, 2015 | $0 | Mar 15, 2017 |
| FY2016 | Mar 31, 2015 | $0 | Mar 15, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($9.89M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($16.08M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($13.87M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($10.44M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.88M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($8.60M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($8.58M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($7.02M) | Mar 19, 2019 |
| FY2016 | Dec 31, 2016 | ($1.37M) | Mar 15, 2017 |
| FY2016 | Sep 30, 2016 | ($1.57M) | Mar 15, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($11.99M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($15.84M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($13.90M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($10.44M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.91M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($8.69M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($8.59M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($8.97M) | Mar 19, 2019 |
| FY2016 | Dec 31, 2016 | ($1.67M) | Mar 15, 2017 |
| FY2016 | Sep 30, 2016 | ($2.99M) | Mar 15, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.30M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $11.61M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $9.17M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $5.91M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.58M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $4.59M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $4.60M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $5.48M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $5.47M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.02M | Mar 15, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($10.58M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($11.54M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($15.10M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($9.92M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.96M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($8.36M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($6.12M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($7.96M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($8.15M) | Apr 2, 2018 |
| FY2013 | Dec 31, 2013 | ($2.31M) | Mar 31, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $21.0K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $70.0K | Mar 30, 2023 |
| FY2019 | Dec 31, 2019 | $0 | Mar 5, 2020 |
| FY2019 | Dec 31, 2018 | $17.0K | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $538.0K | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $338.0K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 15, 2017 |
| FY2016 | Dec 31, 2014 | $123.0K | Mar 15, 2017 |
| FY2015 | Dec 31, 2013 | $0 | Mar 15, 2016 |
| FY2014 | Dec 31, 2012 | $0 | Mar 16, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.88M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $3.22M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $15.97M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $26.57M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $16.48M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $22.66M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.55M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $8.86M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $12.20M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $10.76M | Mar 15, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.73M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $2.78M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.80M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $1.11M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.41M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.57M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.33M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $791.0K | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $3.96M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $937.0K | Mar 15, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $154.0K | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $441.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $14.17M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $25.46M | Mar 30, 2023 |
| FY2022 | Dec 31, 2020 | $15.07M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $21.09M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $1.22M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $8.07M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $8.24M | Mar 19, 2019 |
| FY2017 | Dec 31, 2015 | $9.82M | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($117.50M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($107.61M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($91.53M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($77.66M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($67.22M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($56.34M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($47.74M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($39.16M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($32.13M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($25.38M) | Mar 15, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (4) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | (33) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (38) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (4) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | (33) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (38) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 10, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 5.77M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | 618,000 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 398,000 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 7.16M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 4.54M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 3.69M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 680,000 | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 567 | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | 9,564 | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 89.76M | Mar 15, 2017 |